[go: up one dir, main page]

MX2009002091A - Metodos para reducir las concentraciones de glucosa. - Google Patents

Metodos para reducir las concentraciones de glucosa.

Info

Publication number
MX2009002091A
MX2009002091A MX2009002091A MX2009002091A MX2009002091A MX 2009002091 A MX2009002091 A MX 2009002091A MX 2009002091 A MX2009002091 A MX 2009002091A MX 2009002091 A MX2009002091 A MX 2009002091A MX 2009002091 A MX2009002091 A MX 2009002091A
Authority
MX
Mexico
Prior art keywords
methods
glucose levels
lowering glucose
patient
lowering
Prior art date
Application number
MX2009002091A
Other languages
English (en)
Inventor
Hertzel Gerstein
Salim Yusuf
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MX2009002091A publication Critical patent/MX2009002091A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención se refiere a métodos para reducir las concentraciones de glucosa en un paciente; más específicamente, la presente invención se dirige a métodos para reducir las concentraciones de glucosa que comprenden administrar una cantidad terapéuticamente eficaz de ramiprilo a un paciente con necesidad del mismo.
MX2009002091A 2006-08-28 2007-08-14 Metodos para reducir las concentraciones de glucosa. MX2009002091A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84085006P 2006-08-28 2006-08-28
PCT/EP2007/007160 WO2008025450A1 (en) 2006-08-28 2007-08-14 Methods of lowering glucose levels

Publications (1)

Publication Number Publication Date
MX2009002091A true MX2009002091A (es) 2009-03-09

Family

ID=38578487

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002091A MX2009002091A (es) 2006-08-28 2007-08-14 Metodos para reducir las concentraciones de glucosa.

Country Status (12)

Country Link
US (1) US20080188538A1 (es)
EP (1) EP2059242A1 (es)
JP (1) JP2010501604A (es)
KR (1) KR20090042976A (es)
CN (1) CN101573110A (es)
AU (1) AU2007291602B2 (es)
BR (1) BRPI0716411A2 (es)
CA (1) CA2661598A1 (es)
IL (1) IL197189A0 (es)
MX (1) MX2009002091A (es)
NO (1) NO20090926L (es)
WO (1) WO2008025450A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
DE3226768A1 (de) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3413710A1 (de) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
CA2026686A1 (en) * 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
MXPA02001694A (es) * 1999-08-30 2002-08-06 Aventis Pharma Gmbh Uso de inhibidores del sistema renina-angiotensina en la prevencion de eventos cardiovasculares.
US20050065203A1 (en) * 2001-10-17 2005-03-24 Salim Yusuf Method of reducing type 2 diabetes in high risk patients
WO2003032963A2 (en) * 2001-10-17 2003-04-24 Aventis Pharma Deutschland Gmbh Method of reducing type 2 diabetes in high risk patients
CA2458288A1 (en) * 2003-03-11 2004-09-11 Institut De Cardiologie De Montreal / Montreal Heart Institute Method and compound to reduce the incidence of diabetes in a subject with chronic heart failure

Also Published As

Publication number Publication date
AU2007291602B2 (en) 2012-09-06
KR20090042976A (ko) 2009-05-04
WO2008025450A1 (en) 2008-03-06
JP2010501604A (ja) 2010-01-21
IL197189A0 (en) 2009-12-24
NO20090926L (no) 2009-03-27
BRPI0716411A2 (pt) 2013-09-24
AU2007291602A1 (en) 2008-03-06
CN101573110A (zh) 2009-11-04
EP2059242A1 (en) 2009-05-20
US20080188538A1 (en) 2008-08-07
CA2661598A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
MX2010006823A (es) Metodos para el tratamiento de la gota.
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
IL185808A0 (en) Amide-substituted 8-n-benzimidazoles, metohd for the production thereof, and use of the same as medicaments
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
MY153408A (en) Novel methods
EP1962839A4 (en) ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
WO2009074247A8 (de) Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
NZ595364A (en) TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION
WO2007130501A3 (en) Combination therapy for treatment of cancer
MX348412B (es) Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.
MX2011009804A (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo.
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
WO2010004031A3 (en) Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
WO2007095609A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder
WO2009074498A8 (en) Medical use of 3- (2, 2, 2-trimethylhydrazinixm) propionate orotate
MX2009002091A (es) Metodos para reducir las concentraciones de glucosa.
WO2007123847A3 (en) Treatment of melanoma

Legal Events

Date Code Title Description
FA Abandonment or withdrawal